REGN2477+REGN1033 + Matching placebo
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sporadic Inclusion Body Myositis
Conditions
Sporadic Inclusion Body Myositis
Trial Timeline
Feb 19, 2019 → Nov 5, 2020
NCT ID
NCT03710941About REGN2477+REGN1033 + Matching placebo
REGN2477+REGN1033 + Matching placebo is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Sporadic Inclusion Body Myositis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03710941. Target conditions include Sporadic Inclusion Body Myositis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03710941 | Phase 2 | Withdrawn |
Competing Products
7 competing products in Sporadic Inclusion Body Myositis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bimagrumab + Placebo | Novartis | Phase 3 | 77 |
| BYM338 (Bimagrumab) | Novartis | Phase 2/3 | 65 |
| BYM338/bimagrumab + Placebo | Novartis | Phase 2/3 | 65 |
| Everolimus | Novartis | Phase 2 | 52 |
| BYM338 + Placebo | Novartis | Phase 2 | 52 |
| LDE225 0.75% + Vehicle | Novartis | Phase 2 | 52 |
| Vandetanib 300 mg | Sanofi | Pre-clinical | 22 |